Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant
- Saito, Akatsuki
- Tamura, Tomokazu
- Zahradnik, Jiri
- Deguchi, Sayaka
- Tabata, Koshiro
- Anraku, Yuki
- Kimura, Izumi
- Ito, Jumpei
- Yamasoba, Daichi
- Nasser, Hesham
- Toyoda, Mako
- Nagata, Kayoko
- Uriu, Keiya
- Kosugi, Yusuke
- Fujita, Shigeru
- Shofa, Maya
- Monira Begum, M.S.T.
- Shimizu, Ryo
- Oda, Yoshitaka
- Suzuki, Rigel
- Ito, Hayato
- Nao, Naganori
- Wang, Lei
- Tsuda, Masumi
- Yoshimatsu, Kumiko
- Kuramochi, Jin
- Kita, Shunsuke
- Sasaki-Tabata, Kaori
- Fukuhara, Hideo
- Maenaka, Katsumi
- Yamamoto, Yuki
- Nagamoto, Tetsuharu
- Asakura, Hiroyuki
- Nagashima, Mami
- Sadamasu, Kenji
- Yoshimura, Kazuhisa
- Ueno, Takamasa
- Schreiber, Gideon
- Takaori-Kondo, Akifumi
- The Genotype to Phenotype Japan (G2P-Japan) Consortium
- Shirakawa, Kotaro
- Sawa, Hirofumi
- Irie, Takashi
- Hashiguchi, Takao
- Takayama, Kazuo
- Matsuno, Keita
- Tanaka, Shinya
- Ikeda, Terumasa
- Fukuhara, Takasuke
- Sato, Kei
DOIAbstract
SARS-CoV-2オミクロンBA.2.75株（通称ケンタウロス）のウイルス学的性状の解明. 京都大学プレスリリース. 2022-10-12.The SARS-CoV-2 Omicron BA.2.75 variant emerged in May 2022. BA.2.75 is a BA.2 descendant but is phylogenetically distinct from BA.5, the currently predominant BA.2 descendant. Here, we show that BA.2.75 has a greater effective reproduction number and different immunogenicity profile than BA.5. We determined the sensitivity of BA.2.75 to vaccinee and convalescent sera as well as a panel of clinically available antiviral drugs and antibodies. Antiviral drugs largely retained potency but antibody sensitivity varied depending on several key BA.2.75-specific substitutions. The BA.2.75 spike exhibited a profoundly higher affinity for its human receptor, ACE2. Additionally, the...
Add to ORKG